Which has preferable earnings & valuation, LIAN or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A

Is LIAN or ATXI more profitable?

LianBio's return on equity of -33.17% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts rate PULM or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PULM or ATXI more profitable?

Pulmatrix's return on equity of -125.65% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -125.65% -95.19% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts recommend ATXI or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ATXI or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ATXI or GELS?

Gelteq has higher revenue and earnings than Avenue Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A Gelteq $110K 52.48 -$4.30M N/A N/A

Is ATXI or GELS more profitable?

Gelteq's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Gelteq N/A N/A N/A

Do analysts recommend ATXI or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 567.66%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATXI or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Lexaria Bioscience N/A -174.93% -143.89%

Avenue Therapeutics (ATXI) Competitors

$0.50 0.00 (0.00%)

As of 09/24/2026 02:47 PM Eastern

Compare

ATXI vs. LIAN, PULM, SNOA, GELS, and LEXX

Should you buy Avenue Therapeutics stock or one of its competitors? Avenue Therapeutics's main competitors and comparable companies include LianBio (LIAN), Pulmatrix (PULM), Sonoma Pharmaceuticals (SNOA), Gelteq (GELS), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avenue Therapeutics compare to LianBio?

LianBio (NASDAQ:LIAN) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Avenue Therapeutics	Neutral

74.8% of LianBio shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LianBio's return on equity of -33.17% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Summary

LianBio beats Avenue Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Avenue Therapeutics compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Pulmatrix had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Pulmatrix and 0 mentions for Avenue Therapeutics. Pulmatrix's average media sentiment score of 0.26 beat Avenue Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmatrix	Neutral
Avenue Therapeutics	Neutral

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulmatrix has higher revenue and earnings than Avenue Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.77	-$5.16M	-$1.10	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pulmatrix's return on equity of -125.65% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Pulmatrix has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

Summary

Pulmatrix beats Avenue Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Sonoma Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Sonoma Pharmaceuticals	$21.92M	0.28	-$3.17M	-$1.22	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avenue Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

In the previous week, Sonoma Pharmaceuticals had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for Sonoma Pharmaceuticals and 0 mentions for Avenue Therapeutics. Sonoma Pharmaceuticals' average media sentiment score of 0.36 beat Avenue Therapeutics' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Sonoma Pharmaceuticals	Neutral

Avenue Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sonoma Pharmaceuticals beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to Gelteq?

Avenue Therapeutics (NASDAQ:ATXI) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gelteq has higher revenue and earnings than Avenue Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Gelteq	$110K	52.48	-$4.30M	N/A	N/A

Avenue Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

Gelteq's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Gelteq	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for Gelteq and 0 mentions for Avenue Therapeutics. Gelteq's average media sentiment score of 0.21 beat Avenue Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Gelteq	Neutral

Summary

Gelteq beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to Lexaria Bioscience?

Avenue Therapeutics (NASDAQ:ATXI) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Avenue Therapeutics has higher earnings, but lower revenue than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Lexaria Bioscience	$710K	7.83	-$11.90M	-$5.10	N/A

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience's return on equity of -174.93% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Lexaria Bioscience	N/A	-174.93%	-143.89%

In the previous week, Lexaria Bioscience had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Lexaria Bioscience and 0 mentions for Avenue Therapeutics. Lexaria Bioscience's average media sentiment score of 0.26 beat Avenue Therapeutics' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 567.66%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Avenue Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

Lexaria Bioscience beats Avenue Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.65M	$12.48B	$7.26B	$13.15B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	0.03	792.34	274.71	25.82
Price / Sales	N/A	1,001.22	681.56	110.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.26	10.62	10.46	6.32
Net Income	-$10.38M	$2.81B	$3.49B	$359.77M
7 Day Performance	4.69%	-0.95%	-1.23%	-0.10%
1 Month Performance	21.95%	-2.82%	-4.49%	-4.01%
1 Year Performance	-44.41%	2.73%	16.46%	6.23%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.50 flat	N/A	-37.5%	$1.65M	N/A	0.03	4	Gap Down
LIAN LianBio	N/A	$0.06 flat	N/A	-0.3%	$6.43M	N/A	N/A	110
PULM Pulmatrix	0.4317 of 5 stars	$1.70 +0.9%	N/A	-63.3%	$6.21M	$7.81M	N/A	2	Short Interest Increase Gap Up
SNOA Sonoma Pharmaceuticals	0.2098 of 5 stars	$1.24 -0.8%	N/A	-69.5%	$5.94M	$19.53M	N/A	260	News Coverage
GELS Gelteq	0.7035 of 5 stars	$0.55 -8.5%	N/A	-62.1%	$5.89M	$165.65K	N/A	8	Analyst Forecast Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIAN, PULM, SNOA, GELS, and LEXX

How does Avenue Therapeutics compare to LianBio?

Summary

How does Avenue Therapeutics compare to Pulmatrix?

Summary

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to Gelteq?

Summary

How does Avenue Therapeutics compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIAN, PULM, SNOA, GELS, and LEXX

How does Avenue Therapeutics compare to LianBio?

Which has preferable earnings & valuation, LIAN or ATXI?

Which has more risk and volatility, LIAN or ATXI?

Does the media favor LIAN or ATXI?

Do institutionals and insiders hold more shares of LIAN or ATXI?

Is LIAN or ATXI more profitable?

Summary

How does Avenue Therapeutics compare to Pulmatrix?

Does the media favor PULM or ATXI?

Do insiders & institutionals believe in PULM or ATXI?

Which has preferable valuation and earnings, PULM or ATXI?

Do analysts rate PULM or ATXI?

Is PULM or ATXI more profitable?

Which has more risk and volatility, PULM or ATXI?

Summary

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Which has better earnings & valuation, ATXI or SNOA?

Do analysts recommend ATXI or SNOA?

Is ATXI or SNOA more profitable?

Does the media favor ATXI or SNOA?

Which has more volatility and risk, ATXI or SNOA?

Do insiders and institutionals have more ownership in ATXI or SNOA?

Summary

How does Avenue Therapeutics compare to Gelteq?

Do institutionals and insiders hold more shares of ATXI or GELS?

Which has higher valuation & earnings, ATXI or GELS?

Which has more risk & volatility, ATXI or GELS?

Is ATXI or GELS more profitable?

Do analysts rate ATXI or GELS?

Does the media prefer ATXI or GELS?

Summary

How does Avenue Therapeutics compare to Lexaria Bioscience?

Which has stronger valuation & earnings, ATXI or LEXX?

Do insiders and institutionals have more ownership in ATXI or LEXX?

Is ATXI or LEXX more profitable?

Does the media refer more to ATXI or LEXX?

Do analysts recommend ATXI or LEXX?

Which has more volatility and risk, ATXI or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools